AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
View Patent ↗AT 4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT 4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
1. A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT 4 receptor ligand, having a structure selected form the group consisting of NH 3 + -norleucine-tyrosine-isoleucine-histidine-COO − (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH 2 SEQ ID NO: 1); and administering the AT 4 receptor ligand.
2. A method of inihibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT 4 receptor ligand having a structure of: norleucine-tyrosine-lucine-Ψ-(CH 2 -NH 2 ) 3-4 -histidine-proline-phenylalanine-COO − (SEQ ID NO 3; and administering the AT 4 receptor ligand.
3. The method of inhibiting angiogenesis according to claim 1 or claim 2 , further comprising the delivery of the AT 4 receptor ligand locally.
4. The method of inhibiting angiogenesis according to claim 1 or claim 2 , further comprising the delivery of the AT 4 receptor ligand intravascularly.
5. The method of inhibiting angiogenesis according to claim 1 or claim 2 , further comprising the delivery of the AT 4 receptor ligand intramuscularly.
6. The method of inhibiting angiogenesis according to claim 1 or claim 2 , further comprising the delivery of the AT 4 receptor ligand intraperitoneally.
7. The method of inhibiting angiogenesis according to claim 1 or claim 2 , further comprising the delivery of the AT 4 receptor ligand subcutaneously.
8. The method of inhibiting angiogenesis according to claim 1 or claim 2 , further comprising the delivery of the AT 4 receptor ligand orally.
9. A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT 4 receptor ligand, having a structure selected from the group consisting of: NH 3 + -norleucine-tyrosine-isoleucine-histidine-COO − (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH 2 (SEQ ID NO: 1); and administering the AT 4 receptor ligand.
10. A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT 4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH 2 -NH 2 ) 3-4 -histidine-proline-phenylalanine-COO − (SEQ ID NO: 3; and administering the AT 4 receptor ligand.
11. The method of inhibiting the growth and metastasis of solid tumors according to claim 9 or claim 10 , further comprising delivery of the AT 4 receptor ligand locally.
12. The method of inhibiting the growth and metastasis of solid tumors according to claim 9 or claim 10 , further comprising the delivery of the AT 4 receptor ligand intravascularly.
13. The method of inhibiting the growth and metastasis of solid tumors according to claim 9 or claim 10 , further comprising the delivery of the AT 4 receptor ligand intramuscularly.
14. The method of inhibiting the growth and metastasis of solid tumors according to claim 9 or claim 10 , further comprising the delivery of the AT 4 receptor ligand intraperitoneally.
15. The method of inhibiting the growth and metastasis of solid tumors according to claim 9 or claim 10 , further comprising the step of applying the AT 4 receptor ligand subcutaneously.
16. The method of inhibiting the growth and metastasis of solid tumors according to claim 9 or claim 10 , further comprising the step of applying the AT 4 receptor ligand orally.
17. A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT 4 receptor ligand, having a structure selected from the group consisting of: NH 3 + -norleucine-tyrosine-isoleucine-histidine-COO − (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH 2 (SEQ ID NO: 1); and administering the AT 4 receptor ligand.
18. A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT 4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH 2 -NH 2 ) 3-4 -histidine-proline-phenylalanine-COO − (SEQ ID NO: 3); and administering the AT 4 receptor ligand.
19. The method of inhibiting the growth and metastasis of breast cancer according to claim 17 or claim 18 , further comprising the delivery of the AT 4 receptor ligand locally to the tumor.
20. The method of inhibiting the growth and metastasis of breast cancer according to claim 17 or claim 18 , further comprising the delivery of the AT 4 receptor ligand intravascularly.
21. The method of inhibiting the growth and metastasis of breast cancer according to claim 17 or claim 18 , further comprising the delivery of the AT 4 receptor ligand intramuscularly.
22. The method of inhibiting the growth and metastasis of breast cancer according to claim 17 or claim 18 , further comprising the delivery of the AT 4 receptor ligand intraperitoneally.
23. The method of inhibiting the growth and metastasis of breast cancer according to claim 17 or claim 18 , further comprising the delivery of the AT 4 receptor ligand subcutaneously.
24. The method of inhibiting the growth and metastasis of breast cancer according to claim 17 or claim 18 , further comprising the delivery of the AT 4 receptor ligand orally.